• Atorvastatin in Cholesterol and Ferroptosis Research Workflo

  2026-05-25

  Atorvastatin stands apart as both a gold-standard HMG-CoA reductase inhibitor for cholesterol metabolism research and a novel tool for ferroptosis-driven cancer studies. This guide delivers actionable protocols, data-backed troubleshooting, and advanced applications—positioning APExBIO’s Atorvastatin as an indispensable resource for cardiovascular and oncology labs.

• L-Alanyl-L-Glutamine: Stable Dipeptide for GI Barrier Resear

  2026-05-24

  L-Alanyl-L-Glutamine (SKU B8228) addresses instability and solubility challenges of glutamine supplementation in gastrointestinal research workflows. It is especially useful where intestinal mucosa protection, barrier function enhancement, and antioxidant support are required. Avoid use in assays relying on DMSO or ethanol solubility, or in protocols needing extended aqueous storage.

• 2,5-di-tert-butylbenzene-1,4-diol: Workflow Advances in Calc

  2026-05-23

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) streamlines experimental control over calcium homeostasis and stem cell mobilization, offering reproducible SERCA inhibition for advanced cell signaling studies. Explore protocol enhancements, troubleshooting, and unique comparative advantages backed by recent landmark research.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Advanced Ap

  2026-05-22

  The JC-1 Mitochondrial Membrane Potential Assay Kit empowers researchers with sensitive, ratiometric ΔΨm quantification, crucial for apoptosis and mitochondrial function analysis. This guide unpacks practical workflows, optimization strategies, and real-world troubleshooting to maximize assay performance in cutting-edge immunomodulation and drug discovery studies.

• A23187, Free Acid: Applied Workflows for Calcium Ionophore R

  2026-05-22

  A23187, free acid is a gold-standard calcium ionophore enabling precise control of intracellular Ca2+ for dissecting signaling, apoptosis, and contractility in vitro. This guide delivers actionable protocol enhancements, troubleshooting insights, and a bridge to advanced drug response evaluation workflows, all grounded in the latest cancer research methodology.

• DFO (9H-1,8-Diazafluoren-9-one): Unveiling Molecular Specifi

  2026-05-21

  Explore the advanced molecular mechanisms and forensic applications of DFO (9H-1,8-Diazafluoren-9-one) for latent fingerprint detection. This in-depth analysis reveals insights beyond standard workflows, highlighting DFO's chemical specificity and its pivotal role in forensic science.

• YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol: Proto

  2026-05-21

  YC-1 is a dual-action sGC activator and HIF-1α inhibitor that transforms hypoxia, angiogenesis, and cancer biology assays. This guide delivers actionable workflows, troubleshooting tips, and key translational insights for maximizing the impact of YC-1 in advanced research.

• Amt-1: A Dual-Action Adamantane Derivative Against Resistant

  2026-05-20

  The reference study introduces Amt-1, an adamantane derivative that enhances antiviral defense against influenza A virus by combining direct M2 inhibition with host-directed immunomodulation via the Nrf2/HO-1 pathway. This dual mechanism addresses the challenge of drug resistance and excessive inflammation, suggesting a promising direction for future influenza therapies.

• Optimizing Fluorescent Protein Expression with mCherry mRNA

  2026-05-20

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) empowers robust, immune-silent red fluorescent protein expression for high-precision cell labeling and reporter assays. Its advanced Cap 1 structure and nucleotide modifications unlock reproducibility and translational efficiency even in challenging experimental models.

• Magnetic Nano-antibodies Enable In Vivo CAR-T Mimicry for Tu

  2026-05-19

  This reference study presents a magnetic bispecific nano-antibody (M-BiNanoAb) platform to generate and direct CAR-T-mimicking cells in vivo for solid tumor therapy. The approach effectively enhances T cell infiltration and cytotoxicity in the tumor microenvironment, overcoming major limitations of conventional CAR-T strategies.

• Cy5.5 NHS Ester: Illuminating Tumor Microbiome Dynamics In V

  2026-05-19

  This article reveals how Cy5.5 NHS ester (non-sulfonated) empowers translational researchers to visualize and interrogate tumor-microbiome interactions in real time. By integrating mechanistic insight, protocol recommendations, and frontier findings from cancer metastasis studies, we bridge the gap between optical chemistry and clinically relevant discovery, offering actionable guidance for next-generation in vivo fluorescence imaging.

• α-Amanitin in Transcriptional Regulation: Workflows & Troubl

  2026-05-18

  α-Amanitin empowers researchers to dissect RNA polymerase II–mediated transcription with unmatched specificity, making it indispensable for gene expression pathway analysis and developmental biology. This guide delivers experimentally validated workflows, troubleshooting strategies, and insights from recent chromatin reorganization studies to elevate transcriptional research.

• JNJ-10198409: Precision Platelet-Derived Growth Factor Recep

  2026-05-18

  JNJ-10198409 empowers researchers with nanomolar-level inhibition of PDGF-BB receptor activity, enabling robust tumor growth and angiogenesis studies. Its ATP-competitive mechanism and high solubility make it a go-to compound for advanced cancer biology and fibrotic disorder research workflows.

• Reliable Cell Assays with EZ Cap™ EGFP mRNA (5-moUTP): Scena

  2026-05-17

  This article unpacks real laboratory scenarios where inconsistent reporter gene expression, immune activation, or workflow inefficiencies undermine cell viability and proliferation assays. By leveraging the advanced design of EZ Cap™ EGFP mRNA (5-moUTP) (SKU R1016), researchers gain reproducible, immune-evasive, and robust fluorescent readouts—streamlining mRNA delivery for gene expression studies and in vivo imaging. Practical, evidence-based guidance supports rigorous results and experimental confidence.

• ATRX Loss Sensitizes High-Grade Glioma to PDGFR Inhibition

  2026-05-16

  This study demonstrates that ATRX-deficient high-grade glioma cells exhibit heightened sensitivity to receptor tyrosine kinase (RTK) and PDGFR inhibitors. The findings suggest ATRX status should be considered when evaluating targeted therapies, offering new avenues for precision oncology in glioblastoma.

400 records 7/27 page Previous Next First page 上5页 678910 下5页 Last page